Improving the prognosis of patients with chemoresistant lymphomata
12/18/2013
To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate.
Public, patients, and doctors confuse palliative care with end of life care
12/18/2013
A new review says palliative care's association with end of life has created an "identity problem" that means the majority of patients facing a serious illness do not benefit from treatment of the physical and psychological symptoms that occur throughout their disease.
Evidence of Savings in Accountable Care Organizations and Cancer Care
12/18/2013
Approximately 10 percent of Medicare spending is for cancer care, and Medicare spending is nearly four times higher for beneficiaries with cancer than in those without the disease. Little is known about how to curb spending growth while maintaining or improving quality of care for these high-risk, high-cost patients.
For women with metastatic breast cancer who had elevated amounts of circulating tumor cells (CTCs) in their blood after a first line of chemotherapy, switching immediately to a different chemotherapy did not improve overall survival or time to progression, according to the results of a phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.
The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial.
Progression of advanced breast cancer not delayed by new combination therapy
12/18/2013
Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.
Ultrasound-stimulated microbubbles have been showing promise in recent years as a non-invasive way to break up dangerous blood clots. But though many researchers have studied the effectiveness of this technique, not much was understood about why it works.
Scientists halt first step of breast cancer spread in mice
12/17/2013
The first step in the deadly process of breast cancer metastasis, where tumor cells migrate to other parts of the body, appears to be led by a special class of cells - leader cells - that require the presence of a particular protein to act.
Myriad Genetics, Inc. presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the Myriad's HRD (homologous recombination deficiency) test was significantly associated with cisplatin response in patients with triple negative breast cancer.
Hybrid clotting factor means fewer injections, better disease control for hemophilia patients
12/17/2013
A Phase III clinical trial led by UC Davis researchers has confirmed that a new coagulation factor (rFIXFc) dramatically reduces the number of injections needed to maintain effective clotting for hemophilia B patients. The recombinant protein fuses clotting factor IX with an immunoglobulin (antibody) molecule, which prevents the body from rapidly metabolizing the hybrid protein.